Beijing Zhidao Biotechnology

Beijing Zhidao Biotechnology is a clinical-stage biopharmaceutical company focused on the development of next-generation cytokine therapies and circular mRNA vaccines for oncology and autoimmune diseases. The company utilizes its proprietary LEAD (Low-toxicity, Effective, and Long-acting Drug design) platform to engineer protein drugs with improved safety profiles and extended half-lives. Its lead candidate, ZD003, is an IL-15-based fusion protein currently undergoing clinical evaluation for the treatment of advanced solid tumors. In addition to its protein engineering capabilities, Zhidao Biotech is advancing a circular mRNA platform to develop vaccines and therapeutics with enhanced stability and expression. The company is headquartered in Beijing and has established a comprehensive R&D and manufacturing infrastructure to support its diverse pipeline.